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COMMENTARY
Clinical observation and management of COVID-19 patients
Taisheng Lia, Hongzhou Lub and Wenhong Zhangc
aDepartment of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical
Sciences, Beijing, People’s Republic of China; bShanghai Public Health Clinical Center, Shanghai, People’s Republic of China; cDepartment of
Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
ABSTRACT
Three leading infectious disease experts in China were invited to share their bedside observations in the management of
COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical
course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and
proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are
very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the
quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the
importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu
suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor
Wenhong Zhang is responsible for Shanghai’s overall clinical management of the COVID-19 cases. He introduces the
team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory
supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and
interventions are carefully tailored to the unique characteristics of each patient.
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Since late 2019 to early 2020, the sudden outbreak of
COVID-19, among the general human population in
the City of Wuhan, caused by the transmission of a
novel coronavirus, SARS-CoV-2 [1,2], has led to over
80,000 diagnosed cases including more than 3000
deaths globally as of 29 February 2020. While the over-
all mortality rate for SARS-CoV-2 seems lower than
SARS or MERS, the death rate among severe cases
infected by SARS-CoV-2 is alarming. There are a
wide range of efforts to develop special treatments for
COVID-19 with limited success. In the current com-
mentary, EMI invited three leading infectious disease
experts in China who have personally participated in
the clinical management of COVID-19 cases to share
their bedside observations and to suggest what may
be important in formulating the treatment strategy to
optimize the clinical outcome.
Professor Taisheng Li (being sent to Wuhan
from Beijing to provide frontline care to the
COVID-19 cases in a local hospital)
Since 7 February 2020,my colleagues and Iwent towork
in the intensive care unit (ICU) of Zhongfa Xincheng
Hospital, part of Tongji Hospital in Wuhan. Although
the case fatality rate of COVID-19 is not high, due to
thewidespread of the disease, the total number of deaths
is not small. Based on my observations in the treatment
of severe and critically ill patients in the ICU, I propose
that the early intravenous immunoglobulin (IVIG) and
low molecular weight heparin (LMWH) anticoagula-
tion therapy are very important.
Clinical course of COVID-19
When SARS-CoV-2 infects a person, the lesions are
not limited to the lungs. The virus causes viraemia
after entering the body and the main clinical manifes-
tations are fever, pharyngalgia, fatigue, diarrhoea and
other non-specific symptoms [3,4]. This process
includes the incubation phase and the early phase of
the disease. The incubation takes 1–14 days (3–7
days being common). Peripheral blood leucocytes
and lymphocytes are not significantly reduced (nor-
mal or slightly lower) at this phase. Then, the viruses
spread through the bloodstream and mainly in the
lungs, gastrointestinal tract, and heart, presumably
concentrated in the tissues expressing ACE2, the
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receptor of SARS-CoV-2. This phase occurs around
7–14 after the onset of the symptoms when the
virus starts a second attack, which is also the main
cause of the aggravation of symptoms. At this time,
pulmonary lesions became worse, and chest CT
scans show imaging changes consistent with
COVID-19. At this stage, the peripheral blood lym-
phocytes decrease significantly, involving both T and
B lymphocytes. Inflammatory factors in peripheral
blood are increased.
Abnormal coagulation status
Patients at this phase will begin to develop the hyper-
coagulable state and D-Dimer-based coagulation fac-
tors may appear abnormal. The use of IVIG at this
time may provide patients with effective clinical
benefits and inhibit the formation of inflammatory fac-
tors storm (“cytokine storm”). LWMH therapy,
suggested by colleagues at the Department of Hematol-
ogy, Peking Union Medical College Hospital, may also
alleviate the hypercoagulable state in patients. During
the development of dyspnoea and chest imaging
changes from light to severe, the D-dimer increased
from mild to significant, along with prolonged pro-
thrombin time (PT) and gradual decrease of fibrinogen
(FBG) and platelet. Recently, it has been observed that
some of the non-survivors suffered from ischaemic
changes such as ecchymosis of the fingers and toes
(Figure 1), at the same time as the organ functions of
the heart and kidneys became worse. The above mani-
festations are consistent with the diagnosis of the
hypercoagulable phase of DIC. It is believed that
COVID-2019 can activate coagulation cascade through
various mechanisms, leading to severe hypercoagul-
ability. Early anticoagulation may block clotting
formation and reduce microthrombus, thereby redu-
cing the risk of major organ damages [5,6].
Professor Hongzhou Lu (a leader in China to
try various anti-viral drugs to treat COVID-19
cases)
Considering the clinical and epidemiological character-
istics of COVID-19, the possible effective medications
are in dire need to improve the prognosis of the
patients and to stem the spread of the virus. More
than 200 clinical trials have been organized mainly
for the study of anti-viral drugs including Kaletra,
Remdesivir, Arbidol, Favipiravir, Chloroquine, HCQ,
Darunavir, Lianhua Qingwen Granules and Shuan-
ghuanglian Oral Liquid. While the clinicians are enthu-
siastic about exploring the efficacy of these drugs, these
trials are subject to all kinds of practical limitations.
The majority of the trials are small in scale and repeti-
tive in nature. For instance, a dozen clinical trials on
Chloroquine have been carried out. Furthermore, due
to the difference in design methodology, contradictory
results may arise. The World Health Organization
(WHO) has shown deep concern over the quality of
these clinical trials and has provided guidance. A mul-
titude of domestic experts also contributed their wis-
dom in different ways.
Research design
What we are faced with is a newly discovered viral dis-
ease, testing drugs are selected mainly based on the past
experience of such drugs treating other related diseases.
Someof themonly had in vitro tests. Somehasn’tfinished
Phase II clinical trials. Large-scale clinical trials will take a
long time. Therefore, the small-scale clinical trials,
including Phase II clinical trials, are currently given pri-
ority to, in which case, its effect, proper dosage, themedi-
cation and adverse reaction are initially verified. Those
possibly effective and relatively safe medications can be
coordinated to the large-scale and multi-centre clinical
trials. In this way, a bulk of repetitive trials are avoided.
Another reality situation is the fact that the National
COVID-19 Treatment Guideline has been updated
quite urgently to include possibly effective drugs and
experts are continuously offering new medical sugges-
tions. Therefore, the medical workers in clinical trials
usually take consideration of national guideline and
expert opinion, while carrying out the trial under the
premise that the normal treatment is not affected. As
a result, the intervention group may be covered by a
variety of anti-viral medications. It is difficult to leave
the control group blank in order to confirm the absol-
ute effect of the testing drug in the intervention group.
The specific effects of the testing medication cannot be
verified. In this case, the current clinical studies are not
as rigorous as the traditional clinical trials, but they
Figure 1. Ecchymosis in severe type of COVID-19 patients.
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help draw a quick initial result which can help with the
following study design. It is of vital importance to
motivate the quick publication of clinical trial results,
which can contribute significantly to clinical treatment.
Traditional Chinese medicine
Traditional Chinese medicine, after a long history of
clinical use, has carved out its own theory and practice.
The most typical ones are the “Doctrine of Shanghai”
(febrile diseases caused by exogenous pathogenic fac-
tors) and the “Doctrine of Seasonal Febrile Diseases.”
In the diagnosis and treatment of acute respiratory
infectious diseases like SARS and influenza, traditional
Chinese medicine has played a significant role. But its
treatment determination is based on “Syndrome Differ-
entiation,” in which case, individual plans are produced.
The Chinese medicine formulae are typical of compli-
cated chemical compositions. Thismeans that a creative
evaluation systemof traditionalChinesemedicine needs
to be developed.
Professor Wenhong Zhang (responsible for
Shanghai’s overall clinical management of
the COVID-19 cases)
Since late January, I have been working to ensure the
high-quality care of COVID-19 patient by building a
highly experienced clinician team, Shanghai Clinical
Treatment Expert Group, based on group members’
clinical and scientific expertise to provide the advice
to complicated clinical management.
A team approach to manage COVID-19 patients
Currently, there have been more than 330 laboratory-
confirmed adult cases of COVID-19 in Shanghai [7].
Most patients (>90%) are in mild or moderate states,
and more than 90% of them have been cured and dis-
charged by now. Because no specific drugs have been
shown with clear effectiveness in helping the human
body to clear the SARS-CoV-2 viruses, the disease sever-
ity rate in Shanghai (26 cases, around 9–10%) actually
objectively reflected the natural history of the disease,
and was comparable with the severity rate at other
places outside Hubei Province. All critically ill patients
received invasive mechanical ventilation, and six
patients received extracorporeal membrane oxygen-
ation (ECMO). We found that in addition to the invol-
vement of the respiratory system, critically ill patients
often had systemic involvement of multiple organs,
including the heart, kidney, and coagulation system in
the early disease course. Sometimes multiple system
involvementwas observed even at the time of initial hos-
pital admission. Therefore, in addition to the respiratory
supportive treatment, timelymultiorgan evaluation and
treatment is very crucial.
Every critically ill COVID-19 patient in Shanghai is
managed by a group of healthcare providers which
includes at least a pulmonologist, an infectious diseases
expert, a critical care specialist, and an ECMO specialist
if necessary. Nephrologists, psychiatrists, physicians of
traditional Chinese medicine, experienced nurses also
actively participate in managing these patients as
well. Besides, substantial heterogeneity among severe
patients was noted. Mild patients are more alike, but
each severe case is severe in his/her own way. There
may be multiple pathophysiological mechanisms in
these critically ill patients. The types of critically ill
patients need to be more carefully classified in order
to perform more individualized treatment, in addition
to conducting more dedicated research to develop a
unique management plan. In Shanghai, medical
decisions and interventions are carefully tailored to
the unique characteristics of each severe patient.
Early and effective treatment of mild cases is
critical
The overall mortality rate is about 0.9% in Shanghai.
However, we have found that once the disease course
progressed to the critical illness state (requiring mech-
anical ventilation), the prognosis of the patients would
become significantly worse. From this perspective,
treatments that can prevent mild state from progres-
sing to the severe or critical state will significantly
improve the overall prognosis of the clinical courses.
Such effective treatments include intermittent short-
term haemofiltration (ISVVH), low-dose short-course
glucocorticoids therapy, among other approaches.
The use of glucocorticoids is rather controversial and
there is no general agreement by now. Based on our
experiences, stably mild patients could self-manage
the infection effectively and corticosteroid would not
be recommended for them considering its potential
risks. For patients who have an overly exuberant
inflammatory response or are at high risk of developing
ARDS, early-start of corticosteroids could be helpful.
The benefit of corticosteroids as rescue treatment
remains doubtful.
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